Literature DB >> 31782105

Impact of Arterial Hypertension on Doxorubicin-Based Chemotherapy-Induced Subclinical Cardiac Damage in Breast Cancer Patients.

Domas Vaitiekus1, Gintare Muckiene2, Audrone Vaitiekiene2, Dainora Maciuliene3, Dovile Vaiciuliene2, Grete Ambrazeviciute4, Liveta Sereikaite4, Dovydas Verikas4, Renaldas Jurkevicius2, Elona Juozaityte3.   

Abstract

Advances in oncologic therapies have allowed to achieve better outcomes and longer survival in many patients with breast cancer. Anthracyclines are cytotoxic antibiotics widely used in daily oncology practice. However, anthracyclines cause cardiotoxicity which is a limiting factor of its use. Cumulative dose of anthracyclines is the major cause of induced cardiotoxicity. According to previous clinical trials, the major predisposing high-risk factors for anthracycline-based chemotherapy-induced cardiotoxicity are age, body weight, female gender, radiotherapy, and other diseases such as diabetes and hypertension. Experimental studies in animals confirm that hypertension may be a significant factor predisposing anthracycline-based chemotherapy cardiotoxicity. The main objective of our study was to identify the effect of pre-existing arterial hypertension on the development of subclinical cardiac damage during or after doxorubicin-based chemotherapy in breast cancer patients. The study was performed prospectively between March 2016 and January 2017 in the Hospital of Lithuanian University of Health Sciences Kaunas Clinics Department of Oncology and Department of Cardiology. Data of 73 women with breast cancer treated with doxorubicin-based chemotherapy in outpatient clinic were analyzed. Statistically significant association between pre-existing arterial hypertension and left ventricular systolic dysfunction after completion of chemotherapy was observed (P < 0.004). Our study demonstrated that pre-existing arterial hypertension has a very important role in the development of anthracycline-based chemotherapy-induced cardiotoxicity, despite arterial hypertension control quality. Consequently, further studies evaluating impact of other risk factors and how early and sufficient management of arterial hypertension could influence the development of cardiotoxicity are needed to avoid permanent cardiac damage.

Entities:  

Keywords:  Anthracycline cardiotoxicity; Arterial hypertension; Chemotherapy heart damage; Doxorubicin cardiomyopathy

Mesh:

Year:  2020        PMID: 31782105     DOI: 10.1007/s12012-019-09556-3

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  5 in total

1.  Development of a multivariable clinical prediction model for liposomal doxorubicin-induced cardiotoxicity in adult breast cancer patients: a retrospective multicenter study.

Authors:  Yiqi Sun; Yaodong Ping; Simeng Miao; Zhe Li; Chen Pan; Su Shen; Xingang Li
Journal:  Ann Transl Med       Date:  2022-05

2.  Risk Factors for Anthracycline-Induced Cardiotoxicity in Breast Cancer Treatment: A Meta-Analysis.

Authors:  Meilin Zhang; Hongguang Yang; Changcun Xu; Feng Jin; Ang Zheng
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

3.  Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study.

Authors:  Marilyn L Kwan; Richard K Cheng; Carlos Iribarren; Romain Neugebauer; Jamal S Rana; Mai Nguyen-Huynh; Zaixing Shi; Cecile A Laurent; Valerie S Lee; Janise M Roh; Hanjie Shen; Eileen Rillamas-Sun; Margarita Santiago-Torres; Dawn L Hershman; Lawrence H Kushi; Heather Greenlee
Journal:  J Clin Oncol       Date:  2022-01-13       Impact factor: 50.717

Review 4.  Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity.

Authors:  Marwa Tantawy; Frances G Pamittan; Sonal Singh; Yan Gong
Journal:  Clin Transl Sci       Date:  2020-08-28       Impact factor: 4.689

5.  Comorbidities and mortality risk among extensive-stage small-cell lung cancer patients in mainland China: impacts of hypertension, type 2 diabetes mellitus, and chronic hepatitis B virus infection.

Authors:  Weigang Xiu; Yin Huang; Yanying Li; Min Yu; Youling Gong
Journal:  Anticancer Drugs       Date:  2022-01-01       Impact factor: 2.248

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.